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Abstract
Background: Intimate partner abuse (IPA) is a major public health problem with serious implications for the
physical and psychosocial wellbeing of women, particularly women of child-bearing age. It is a common, hidden
problem in general practice and has been under-researched in this setting. Opportunities for early intervention and
support in primary care need to be investigated given the frequency of contact women have with general
practice. Despite the high prevalence and health consequences of abuse, there is insufficient evidence for
screening in primary care settings. Furthermore, there is little rigorous evidence to guide general practitioners (GPs)
in responding to women identified as experiencing partner abuse. This paper describes the design of a trial of a
general practice-based intervention consisting of screening for fear of partner with feedback to GPs, training for
GPs, brief counselling for women and minimal practice organisational change. It examines the effect on women’s
quality of life, mental health and safety behaviours.
Methods/Design: weave is a cluster randomised controlled trial involving 40 general practices in Victoria,
Australia. Approximately 500 women (16-50 years) seen by the GP in the previous year are mailed a short lifestyle
survey containing an item to screen for IPA. Women who indicate that they were afraid of a partner/ex-partner in
the last year and provide contact details are invited to participate. Once baseline data are collected, GPs are
randomly assigned to either a group involving healthy relationship and responding to IPA training plus inviting
women for up to 6 sessions of counselling or to a group involving basic education and usual care for women.
Outcomes will be evaluated by postal survey at 6 and 12 months following delivery of the intervention. There will
be an economic evaluation, and process evaluation involving interviews with women and GPs, to inform
understanding about implementation and outcomes.
Discussion: The weave trial responds to an urgent need for more evidence on what can be achieved in primary
care with regard to responding to women who experience IPA. It will provide important knowledge about the
effectiveness of a brief method of screening, professional IPA training program and brief counselling for women.
Trail Registration: [ACTRN12608000032358]
Background
Intimate partner abuse (IPA) or violence is defined as
any behaviour within an intimate relationship that
causes physical, psychological or sexual harm to those
in the relationship [1]. Behaviours include acts of physi-
cal aggression such as slapping and kicking;
psychological abuse such as intimidation and humilia-
tion; forced intercourse and other forms of sexual coer-
cion; and various controlling behaviours such as
isolating a person from their family and friends, moni-
toring their movements, and restricting access to infor-
mation or assistance. IPA sits within the broader
context of gendered violence and the majority of
assaults by partners are directed at females [1,2]. More-
over, sexual abuse and partner violence resulting in
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against women by their partners than against men [3].
Partner abuse is a major public health problem globally.
It diminishes women’s capacity to participate in occupa-
tional, social and familial life and contributes to signifi-
cant morbidity and mortality among women of child-
bearing age [4]. IPA is a complex problem arising from
an interplay of personal, situational and socio-cultural
factors [2]. Thus, in addition to the need for multifa-
ceted social and educational interventions, early inter-
vention in healthcare settings is required. Primary care
offers such an opportunity.
Prevalence of IPA
Partner abuse is a common but hidden problem for
women of child-bearing age. Across ten culturally and
economically diverse countries, the World Health Orga-
nisation reported the lifetime prevalence of physical
and/or sexual partner violence as ranging from 15% to
71% [5]. An Australian general practice study found that
almost 30% of women had at some point in their lives
been afraid of a partner [6]. A further GP study using
the Composite Abuse Scale (CAS) [7] to measure abuse
in the previous 12 months reported that 6% of women
of child-bearing age had experienced severe combined
physical, emotional and/or sexual abuse; a further 7%
experienced physical and emotional abuse; 6% experi-
enced physical abuse alone and 6% reported emotional
abuse alone [8]. Similarly, a United Kingdom study
reported that 17% of women attending general practice
had experienced physical violence from a partner/ex-
partner in the previous year [9].
Health consequences of IPA
Partner abuse has been estimated as the leading cause of
death and disability among women of child-bearing age
[10]. Research consistently highlights a range of severe
physical and mental health problems that are associated
with partner abuse [4]. Abused women are at increased
risk of anxiety, depression, post-traumatic stress disor-
der, suicide, and drug and alcohol abuse [8,11,12].
Women indicate that the psychological abuse is even
more difficult to endure than the physical abuse itself
[13]. The most common physical health problems
include injuries, chronic pain and gynaecological, cardio-
vascular, neurological and gastrointestinal problems [14].
Partner abuse may commence, or increase during preg-
nancy affecting up to 1 in 4 pregnant women [13,15]. In
a UK cross-sectional study of women attending general
practice, 15% of respondents who had ever been preg-
nant reported partner violence during pregnancy, with a
quarter reporting that this violence was worse than
when they were not pregnant and almost one third say-
ing that it had caused a miscarriage [9]. Partner abuse is
associated with adverse maternal and infant outcomes e.
g. low birth weight [16], foetal injury and pre-term birth
[17], and even death of the mother or the foetus [18].
Partner abuse also has associations with common mater-
nal physical health issues - back pain, headache, urinary
incontinence and some less common health issues such
as bleeding in first trimester, faecal incontinence [19,20].
Partner abuse also has serious consequences for the
physical and emotional well-being of children who wit-
ness it [21].
IPA and health care
Abused women are overrepresented in outpatient set-
tings and in primary care [22,23]. Approximately a third
of abused women disclose abuse to their GP [24].
Women describe barriers to disclosure that are both
internal (e.g. feeling ashamed and embarrassed) and
external (e.g. perceiving that doctor is only there for
physical problems). GP inquiry is associated with
increased disclosure [24], however only 1 in 10 abused
women are asked about abuse by the GP [24,25]. Yet
there is evidence that women consider it appropriate to
be asked about partner abuse [26]. This is moderated by
the context of the consultation, the relationship with the
health care provider and the woman’sr e a d i n e s st o
address the problem [27]. Reluctance on the part of
health professionals, including GPs, to inquire about
abuse owes to factors such as lack of time and training,
lack of effective interventions and the complexities of
providing whole family care [28,29]. Low levels of
inquiry and disclosure have triggered a shift in research
focus from studies about prevalence, consequences and
patient-health provider interactions to finding improved
approaches to screening and intervention.
Screening
A recent systematic review shows that there is insuffi-
cient evidence to justify implementing screening pro-
grams [30]. Further support came from a recent
Canadian study [31], the first IPA screening trial to
examine health outcomes for women. It included 12 pri-
mary care sites. The authors concluded that there was
not enough evidence to support IPA screening in health
care settings as routinely asking all patients in the inter-
vention group about abuse, though not found to be
harmful, was no more beneficial in terms of health out-
comes than usual care. There was no specific interven-
tion offered to women who were detected by the
screening program. Despite women’s doctors being
informed that they screened positive, half reported that
IPA was not raised in subsequent consultations. A
major criterion for screening that is not being met
relates to the availability of an effective treatment once
abuse is identified/disclosed. This means that IPA fails
to fulfil public health policy criteria for a screening pro-
gram in health care settings [30]. There is therefore an
urgent need for rigorous testing of specific interventions
and services for women following identification of IPA
Hegarty et al. BMC Public Health 2010, 10:2
http://www.biomedcentral.com/1471-2458/10/2
Page 2 of 11[31,32]. IPA screening instruments are increasingly eval-
uated against criterion standards such as the Conflict
Tactics Scale [33] or Composite Abuse Scale [7]. In a
review of 18 brief screening tools in 15 validation stu-
dies, Feder et al. found several to be valid for use in
health care settings [30]. Inquiring about fear of a part-
ner or ex-partner is receiving increased attention [6,34]
and has significant potential as a stand alone screening
item. Abused women attending primary care are much
more likely (OR = 64.1, 95% CI 44.4-94.1) to have been
afraid of a partner or ex-partner at some point in their
lives than non-abused women [6]. The fear question has
been shown to have good sensitivity and specificity for
identifying women who have experienced physical abuse
(75.5% sensitivity, 82.4% specificity) or severe combined
physical, emotional and sexual abuse (85% sensitivity,
77.7% specificity) in a large sample of women attending
GPs for primary care. It does not perform as well in
identifying women who have experienced emotional
abuse alone (60.6% sensitivity, 80.4% specificity) [7]. It
may be concluded that the implementation of screening
for IPA is hampered by the absence of evidence for
intervention following screening, particularly interven-
tion for women in the early stages of recognising and
disclosing abuse. Therefore expanding the evidence base
on the optimal method of screening and effective
responding is a priority.
Interventions for women in health care settings
Ramsay et al. reviewed 19 studies to evaluate the effec-
tiveness of health care interventions for women on phy-
sical and psychosocial wellbeing and their experiences of
abuse [35]. This was recently updated with the addition
of 14 studies, 5 of which focused on children for the
first time [30]. Studies came from diverse settings (e.g.
antenatal clinics, refuges, community settings, primary
care) and variously tested the impact of advocacy, sup-
port group and psychological (individual or group)
interventions on outcomes such as post-traumatic stress
disorder, depression, self-esteem and abuse. Overall, the
evidence was sufficient to recommend access to advo-
cacy services but this only applied to women who had
actively sought help (as opposed to women identified
through screening). Evidence for the effectiveness of
psychological group therapy, support groups, and child
interventions was insufficient on account of too few stu-
dies, poor quality design and lack of data for calculating
effect sizes. There was sufficient evidence to recommend
individual psychological treatments. However, treat-
ments were diverse (e.g. cognitive behavioural therapy,
problem-solving, expressive writing, psycho-education,
feminist-oriented and grief counselling and forgiveness
therapy) and since they largely involved survivors and
those actively seeking assistance, they can be extrapo-
lated neither to women identified through screening nor
those attending primary care settings. There was a clear
absence of qualitative studies examining what women
themselves think should be contained in an intervention
for IPA [30].
Similar to the absence of women’s voices, primary care
was under-represented across these studies and settings.
The review demonstrates the lack of focus on early
intervention and the need f o rm o r ee v i d e n c ea b o u t
woman-centred interventions. While health practitioners
a r ew i d e l ye n c o u r a g e dt oa s s u m ear o l ei ns u p p o r t i n g
abused women, there are limited guidelines available on
how to do this [36]. Most tend to focus on identification
and referral rather than on appropriate ways of respond-
ing to and counselling women following disclosure. It is
imperative to expand the evidence base with respect to
the types of counselling that might be effective for
abused women who screen positive for abuse. This
paper describes the development and design of a trial of
screening and intervention in primary care for women
who have been afraid of a partner or ex-partner in the
last year.
Evidence informing the development and design of
weave
We have outlined in detail [37] the development of the
counselling intervention based on the Transtheoretical
Model of Behaviour Change [38] adapted to partner
abuse [39,40]. We particularly focused on the ‘Psychoso-
cial Readiness Model’ [41] to conceptualise women’s
experiences. We used evidence of best practice from
systematic reviews of health care-based interventions
[30,35] and of qualitative studies with women [27],
international primary care guidelines on partner violence
[36] and evaluation of general practice-based partner
abuse pilots in Australia and overseas. The weave brief
counselling intervention [37] incorporates motivational
interviewing [42] and problem-solving techniques [43],
which have been increasingly applied in the primary
care setting for depression is s u e s[ 4 4 ] .F i n a l l y ,p a r t n e r
abuse interventions frequently aim to improve the safety
of women [45-47], and this forms a core aspect of our
‘Healthy Relationships’ training for GPs.
Outcomes
A key issue in trial design is to identify a set of out-
comes that are important to women experiencing abuse
and selecting an appropriate means of operationalising
these outcomes. Programs focused on women should
not be expected to necessarily produce decreased vio-
lence in women’s lives [48] suggesting that the use of
violent events as a primary outcome in trials may be
problematic. Change that is internal to the woman is
potentially more informative when evaluating the impact
of an intervention for partner abuse, especially one that
involves direct counselling. Indeed it may be that signifi-
cant changes in experience of abuse may not be
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been sown. Instead it may be more effective to focus on
health outcomes for women, such as quality of life and
mental health, which have received limited attention in
trials to date [31,49]. Emergent areas of measurement
include harm - that which potentially emanates from
screening, intervention and from participating in IPA
research [30].
Aims of weave
The primary aim of the weave study is to determine if a
multifaceted intervention consisting of screening for
intimate partner abuse and feedback for GPs, training
for GPs, a brief counselling intervention for women and
minimal practice organisational change results in:
￿ increased quality of life;
￿ increased mental health, and;
￿ increased safety behaviours and planning for
women who experience partner abuse.
The secondary aims are to determine if the interven-
tion results in:
￿ increased readiness for change with regard to the
abuse;
￿ increased comfort on the part of women to discuss
partner abuse with GPs;
￿ increased inquiry by GPs about the safety of
women and children;
￿ reduced anxiety and depression;
and is cost effective.
We hypothesise that the brief counselling intervention
will increase women’s perceived support and comfort to
discuss abuse and lead to positive changes in women’s
self-efficacy and readiness to change, and that these
‘internal’ changes will collectively lead to increases in
safety planning and behaviours and improvement in
mental health and quality of life.
Methods/Design
The study conforms to the guidelines contained in the
CONSORT statement for cluster randomised controlled
trials [50]. Individual GPs (cluster) will be the unit of
randomisation. The study includes one GP only per
practice to circumvent the threat of contamination due
to cross-over effects. Interventions and analyses will tar-
get two levels - the cluster (GP) level and individual
(woman) level. The trial will include 40 GPs and consist
of two arms - intervention and comparison. Figure 1
presents the anticipated flow of clusters and individual
patients over the course of the trial. The study has
received ethics approval from the Human Research
Ethics Committee of The University of Melbourne.
Inclusion and exclusion criteria
General practitioners
GPs will be eligible if they work three or more sessions
per week and are based at a computerised practice. GPs
will be excluded if 30% or more of their patients are
non-English speaking or if the GP has not been actively
practising in the last 12 months.
Women
Women will be eligible for the initial screening compo-
nent of the study if they have consulted the participating
GP within the last 12 months and are aged between 16
and 50 years. Women will be excluded if, in exercising
clinical judgement, the GP anticipates they may encoun-
ter difficulties in providing informed consent, under-
standing the content of surveys and/or participating in
other aspects of the study due to mental or physical
health issues, cognitive impairment, intellectual disability
or poor English language skills. Additional criteria are
required for inclusion in the trial - women will be
invited to participate (over the telephone) if they indi-
cate in the screening survey that they have been afraid
of their partner or ex-partner in the last 12 months and
are interested in hearing more about the weave project.
Women will be excluded at this stage if it is established
during the recruitment phone call that they no longer
attend the GP or they are a false-positive. False positives
are women who misinterpreted the fear item in that
they have never felt afraid of a partner or they have not
felt afraid in the previous 12 months.
Number of participants required
The final sample size of 89 women in each of the two
groups will have at least 80% power (alpha 5%, 2-sided
test) allowing for a clustering effect (intra-cluster corre-
lation of 0.02 [8]) to detect clinically important differ-
ences on the primary outcomes at 12 months between
the intervention and comparison groups (See Table 1).
To have sufficient power to test our hypotheses, 40
practitioners (20 in each arm) are required in order to
allow screening of approximately 500 women per prac-
tice (20000 women in total). Based on women’s response
rates from the weave pilot study and diamond study
[51] 40% of women will return the screening survey
(8000). Of these, it is estimated that 10% (800) will have
experienced abuse that includes combined physical, sex-
ual and/or emotional abuse in the last 12 months and
will therefore screen positive to having been afraid of a
partner or ex-partner during this period. Of these, 60%
(480) will indicate an interest in hearing more about the
project and being contacted by the research team. It is
estimated that 70% (336) oft h e s ew o m e nw i l la g r e e
over the phone to being involved in the trial (a propor-
tion will decline and a proportion will prove ineligible at
this stage), 80% (268) of whom will return their baseline
surveys and enter the trial. Following randomisation,
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months based on data from the diamond cohort [51]
and MOSAIC [52] leaving 89 women per group at 12
months.
Recruitment
Multiple strategies will be used to recruit GPs. These
include mailing to randomly selected GPs (750 urban,
250 rural; within 150 km radius of Melbourne) regis-
tered with the Australasian Medical Publishing Com-
pany. GPs will be sent a letter of invitation, information
about the project and a faxback form in the mail. If we
still require more GPs, we will re-contact eligible prac-
tices from this original list, and request that the practice
manager advertise the project among GPs with interest
in women’s health, domestic violence, mental health or
research. Additionally, we will mail out to 600 GPs
involved in shared maternity care in Melbourne using
the same protocol.
Although we will utilise the lists described above as
much as possible to minimise selection bias, we will
Figure 1 Flow of participants through trial.
Table 1 Primary outcomes, measures and hypothesised differences between study groups
Outcome Measure/tool Hypothesis
Quality of life World Health Organisation Quality of
Life-Bref [58]
There will be a difference of half of a standard deviation between the two groups
(assuming a SD of 20) [66]
Mental health
status
SF-12 Mental Component Summary [59] There will be a difference of half of a standard deviation (SD = 11) between the two
groups [67]
Safety planning Safety plan in the last 12 months Have a safety plan at 12 months: 10% vs 40%
Safety
behaviours
Safety-Promoting Behaviour Checklist
[60]
There will be a difference of half of a standard deviation (SD= 2.5) between the two
groups [68]
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torian-based general practice research network service
based at the Primary Care Research Unit at The Univer-
sity of Melbourne. Staff from VicReN will assist by
advertising the project in newsletters of the Royal Aus-
tralian College of General Practitioners (RACGP) and
Divisions of General Practice and by engaging GPs
using various strategies. All eligible GPs will be asked to
read and sign a Memorandum of Understanding and
consent form, complete a baseline survey (allowing com-
parison with the Australian GP population) and to com-
plete the basic education kit. Practices are reimbursed at
a rate of $500 for time involved in generating patient
lists and GPs will be eligible for RACGP Quality Assur-
ance and Continuing Professional Development points.
Patient recruitment
Patient recruitment will be done through methods vali-
dated in a recent primary care cohort study that
screened for probable depression via postal survey, and
included a screen for abuse [51]. In weave, for each par-
ticipating GP, a list of female patients, aged 16 to 50
years who consulted the GP at least once in the pre-
vious 12 months will be randomly generated (maximum
600 patients per list). The GP will review the list and
exclude those women who meet exclusion criteria. The
remaining women will be mailed the screening question-
naire together with a letter from their GP endorsing the
project, an information sheet, a resource card listing
contact numbers for various support agencies and a
r e p l yp a i de n v e l o p e .I nt h es u r v e yt h er e s p o n d e n t sa r e
told that the weave team is trying to work out ways to
improve the care women receive in general practice, and
particularly in relation to emotional well-being. At the
end of the screening survey, respondents are asked if
they would like to hear more about weave,t h en e x t
stage of which involves “completing a survey about rela-
tionship and emotional issues (e.g. depression, domestic
violence, stress or worry).” A reminder is mailed out
from the practice to all women 14 days following mail-
out of the screening survey.
Eligible women will be phoned by a research assistant
who will explain the nature of the study (a project look-
ing at ways of improving the care women receive from
their GP when they are experiencing relationship and
emotional issues, such as being afraid of your partner or
ex-partner). It will be explained that the project will
involve three surveys over approximately 18 months and
that they may or may not be invited to see the GP to
discuss relationship and emotional issues depending on
the group in which they are placed by chance. Those
eligible and agreeing to be involved are sent a baseline
survey, information sheet, resource card and a reply
paid envelope. Once the baseline survey and consent
form have been returned, women are officially enrolled
in the trial. A reminder is sent to patients 10 days post
b a s e l i n es u r v e ya n dap h o n ec a l lr e m i n d e ra t2 0d a y s .
All GPs (and their female patients) in a given wave
(there will be four waves) are randomised to interven-
tion or comparison once the cut-off for the return of
the baseline survey (30 days following mail-out) for the
final GP in the wave has been reached.
Sequence generation and allocation concealment
Allocation to intervention or comparison will be based
on clusters rather than individuals. The trial will be run
in four consecutive overlapping waves. Approximately
10 GPs will be randomised in each wave. Characteristics
of GPs, including age, sex, years of general practice
experience and knowledge about management of partner
abuse, will be measured at baseline to check the extent
to which randomisation creates equivalence across the
two groups. To promote comparability of the interven-
tion and comparison clusters with respect to cluster
characteristics, practitioners will be stratified according
to whether they are urban or rural and block randomi-
sation with random block sizes will be used within each
stratum. The randomisation will be performed by a sta-
tistician not directly involved in the study and who is
blinded to the identity of the practitioners. Allocation of
clusters to intervention or comparison will done follow-
ing collection of baseline data. In other words, at the
time of screening and recruitment of women, the alloca-
tion of GPs (and therefore, of women) will be unknown.
Blinding
weave is a pragmatic intervention study. Due to the nat-
ure of the intervention (professional training plus
patient counselling) it is not possible to blind the GPs
to their status as intervention or control. Similarly, the
immediate project team is not blind to GP participant
status as much interaction between the team and the
GPs must occur as part of the training and organising
for women to attend their counselling appointments. In
the same vein, women are not blinded in that they need
to be aware that they may (intervention group) or may
not (comparison group) be invited by the GP to discuss
relationship issues as part of weave.W o m e nw i l lb e
made aware that they will receive surveys regardless of
the group they have been assigned to. There is no blind-
ing as regards data collection based on the CONSORT
guidelines [50], as the women and GPs themselves com-
p l e t et h es u r v e y s( i . e .d a t aw e r en o tc o l l e c t e db ya
research assistant blinded to the allocation). However
the wider investigator team (and the statistician) remain
blinded to the identity and allocation of GP participants
and women.
Intervention
The weave intervention [37] is a multifaceted, practice-
based program refined by the multidisciplinary team
and project reference group. It consists of professional,
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fessional intervention (weave Healthy Relationships
T r a i n i n g )i st ot r a i nG P si nh o wt or e s p o n dt oI P A
when women are identified, and to facilitate GPs to deli-
ver a brief counselling intervention to patients who have
been afraid of their partner or ex-partner. It will equip
practitioners with an innovative, time-efficient and
structured approach to use with patients. The interven-
tion was developed with particular attention to over-
come the challenges of changing physician behaviour
[53] by being practice-based and including group discus-
sion via teleconference, clinical audits, distance learning,
evidence-based guidelines [36] and two interactive prac-
tice visits [37]. Key elements of the visits are active lis-
tening exercises [54], attitudinal exercises [55],
involvement of simulated patients and role play of dif-
ferent readiness for change scenarios [40], use of survi-
vors’ voices [56], and modelling of non-abusive
behaviours in teaching interactions with health providers
[55]. As required, additional practice visits, email and
telephone support will be provided.
The patient component of the weave intervention
involves a brief counselling intervention for delivery by
the intervention (trained) group GPs within the primary
care setting. Female patients who have been ‘afraid’ of a
partner or ex-partner in the last 12 months (participants
in the study) will receive a letter from their GP inviting
them to make an appointment to discuss relationship
and emotional issues. Women will be offered several
30-minute counselling sessions by their GP for relation-
ship issues and their emotional wellbeing. Where
women have not made an appointment within a fort-
night of receiving the invitation the research assistant
will contact them and offer to connect them immedi-
ately with the practice to book an appointment. The
main aim of the weave brief intervention is to assist
women to:
￿ feel listened to, validated and supported by their
GP;
￿ experience increased awareness about the abuse;
￿ increase their readiness for change and self-effi-
cacy, and;
￿ increase their safety planning and behaviours.
At the first visit, the GP establishes with the woman
the number of sessions that might be required (up to 6).
The woman’s readiness for change is established and the
GP then selects motivational interviewing and/or pro-
blem-solving techniques as part of an appropriate
response to the woman’sp o s i t i o n .G P sc o m p l e t e
encounter forms during the women’s visits to allow
gathering of process data on the content of the
counselling.
The minimal organisational change component of the
intervention involves circulating information about
weave to the administrative and clinical staff, placing
posters on the wall and working with the practice staff
to identify suitable and consistent methods of reminder
and recall for the women. Each aspect of the organisa-
tional change will prioritise the confidentiality of women
and will be practice-centred (i.e. guided by advice of the
participating GP and practice manager). At the conclu-
sion of the trial, comparison group GPs will be invited
to participate in a day long workshop based on the
weave Healthy Relationships Training Program.
Data collection
Outcome evaluation
Data will be collected from women by postal question-
naire at the screening stage and at three further points
over the duration of the project. Similar to other studies
in this area [30,31], we will collect data from women in
both groups at baseline, and at 6 and 12 months follow-
ing the invitation to the intervention group women to
attend counselling. Development of study materials has
been informed by a primary care cohort study on
depression which also gathered data on abuse [51].
Screening phase
The primary purpose of the screening questionnaire is
to identify women who have been afraid of a partner or
ex-partner in the last 12 months and of those, the
women willing to be contacted by the project team. The
additional items in the survey ask about depression,
smoking, alcohol, anxiety, dietary issues and exercise.
These help to conceal the purpose of the survey and
protect participants. Responses are on a five point likert
scale ranging from ‘None of the time’ to ‘All of the
time’. If a woman selects an option other than ‘None of
the time’ for the afraid question, and indicates an inter-
est in hearing more about the project, then she is con-
tacted and invited to participate in the trial. Other items
include a sub-dimension of the General Practice Assess-
ment Questionnaire [57] and sociodemographic items.
We also included items to establish whether women
have disclosed being afraid to a GP previously, if they
would use help from the GP or general practice nurse if
it were available and how comfortable they would be
discussing feeling afraid with the GP. It is explained in
the screen survey that not every woman who provides
her contact details can be contacted by the project team.
Trial phase
The primary outcomes (Table 1) include quality of life,
measured across four dimensions (physical, psychologi-
cal, environmental, social) using the WHOQoL-Bref
[58], and mental health status, using the mental compo-
nent of the SF-12 [59]. The third primary outcome is
safety and is measured based on the existence of a safety
plan (yes/no) and the number of safety behaviours
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The secondary outcomes include open ended questions
about readiness for change, based on the Domestic Vio-
lence Survivor Assessment [61], comfort to discuss
abuse with GP (5-point likert scale), GPs’ inquiry about
the safety of women and their children (yes/no) and
anxiety and depression, based on the Hospital Anxiety
and Depression Scale [62]. Health care utilisation is
measured based on visits to health professionals, days
out-of-role and hospital admissions. Other variables
measured at different stages of the trial were included to
investigate mediating variables (see Table 2) and to pro-
vide process data to help understand why the interven-
tion may or may not have been effective. Harm
associated with participation in the research (e.g. accept-
ability of screening, distress caused by being invited into
the project, partner’s awareness of the research, adverse
effects arising from participating in counselling,
response burden) was measured using an adapted ver-
sion of the COST questionnaire [31].
The readiness of GPs to manage intimate partner
abuse is assessed before and after the training using
PREMIS, a validated questionnaire assessing knowledge,
attitude and behaviours of doctors with regard to IPA
[63].
Economic evaluation
The primary economic evaluation will use a cost-conse-
quences analysis, with any incremental costs compared
to all incremental outcomes as detailed above. If this
does not reveal a dominant result for the cost-effective-
ness of the intervention, secondary economic analysis
will involve incremental cost-effectiveness analysis using
individual outcome measures and cost-utility analysis
using SF-12 data. The economic evaluation will be
conducted from both a health care and societal perspec-
tive, with costs including resources used in intervention
delivery and practice-based system change and women’s
use of health care and other societal resources.
Process evaluation
The Realistic Evaluation model was used in the trial to
develop a causal model (Figure 2) to allow understand-
ing of ‘what works for whom in what circumstances?’
[64]. This evaluative framework examines context,
mechanism and outcomes. Process data will include
completion of encounter forms describing what GPs did
during the sessions e.g. counselling methods used, bill-
ing, follow-up and written plans. In addition we will ask
GPs to audio-record consultations. We anticipate that
only a small proportion of GPs and women will agree to
have the sessions recorded. We will conduct semi-struc-
tured interviews with a sample of up to 20 women from
each arm of the trial after the 12 month assessment. We
will purposively sample the women such that a range of
women’s level of fear, severity of abuse and their readi-
ness to change at baseline are represented. The purpose
will be to assess their experiences of receiving the inter-
vention or usual care and perceived outcomes. We will
gather data on satisfaction with counselling sessions/
usual care, extent to which expectations of sessions/
usual care were met, changes to usual GP care, quality
of relationship with GP, experiences of being in the pro-
ject, relationship with research team, and any changes
women made in their relationships as a result of being
involved in weave. Individual semi-structured telephone
interviews with all GPs from both comparison and inter-
vention at the end of the trial will assess their percep-
tions of the research and intervention process and the
impact on their practice, both positive and negative. We
will ask about satisfaction with training and counselling
process/usual care, perceived impact of counselling/
usual care on women, whether expectations of being
involved in weave were met and perceived impact on
their practice and sustainability of skills and practice.
Data from all sources including the 6 month patient
surveys will be combined to understand what works for
whom in what circumstances.
Data analysis and reporting
Characteristics of GPs and women will be summarised
using frequencies and percentages for categorical data,
and means and standard deviations or percentiles for con-
tinuous data, for the two study arms. GP and women’s
characteristics will be compared between the two arms at
recruitment to ensure that randomisation was effective.
Intra-cluster correlations will be calculated for key out-
come variables and patient variables at baseline. Appropri-
ate modelling techniques will be used to account for the
complexity of the study design, its hierarchical structure
(women clustered within practices), stratification of
Table 2 Other variables and measures included in 6 and
12 month surveys
Variable Measure/tool
Sense of safety How safe have you felt at home in the last two
weeks/6/12 months ago? (visual analogue scale)
Safety behaviours What things do you do (or have you done in the
last 6 months) to keep you safe from your
partner or ex-partner? (open-ended question)
Nature/frequency of
abuse
Composite Abuse Scale [7]
Health status Short Form-12 (PCS) [59]
Smoking
Alcohol (AUDIT) [69]
Medications (analgesics, antidepressants and
sedatives)
Post-traumatic stress
disorder
Short Screening Scale for DSM-IV PTSD [70]
Self-esteem and self-
efficacy
Rosenberg Self-Esteem Scale [71]
Generalized Self-Efficacy Scale [72]
Social support Oslo 3 Social Support [73]
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Page 8 of 11practices at randomisation and repeated measures over
time. GP practice will be set as the primary sampling unit
and analysis will be intention-to-treat. Marginal logistic
regression using Generalised Estimating Equations (GEE)
with information sandwich estimates of standard error will
be used for the binary outcomes. Mixed-effects linear
regression will be used to compare the scores between the
two study groups for mental health status and quality of
life measures. Baseline outcome measures and any imbal-
anced factors strongly associated with the outcomes will
be adjusted for in the regression model. An independent
data monitoring committee (DMC) consisting of 5 mem-
bers (GP/researcher, IPA researcher, community service
worker, GP, and a statistician) will be convened on
approximately four occasions over the course of the trial.
The aim of the weave DMC is to monitor the safety of the
participants and ensure the integrity of the trial data. This
will be achieved by checking interim data and monitoring
progress against the trial protocol including recruitment
rates, uptake of the intervention and loss to follow-up.
Discussion
In summary, there is a strong rationale for developing
and testing interventions of screening and counselling
for women who experience partner abuse, for embed-
ding this research in primary care and for measuring
the effect in terms of health outcomes for women. Pri-
mary care allows considerable scope in terms of the
women who are reached, and is unique in that it has
the potential to facilitate early intervention as well as
support for women who are in recovery but remain at
risk. Notwithstanding the challenges [65], well-designed
randomised controlled trials are essential for testing
hypotheses with strong theoretical underpinnings to
produce high quality evidence [30]. Evaluation needs to
incorporate adequate follow-up and a focus on safety
and health outcomes for women. Finally, process mea-
surement is essential to explain the ‘why and how’ of
the intervention, focusing on areas such as uptake of
intervention, harm, readiness for change, inquiry by
health professionals, abuse, support, self-efficacy and
expectations. With intimate partner abuse the leading
contributor to death, disability and illness among Vic-
torian women aged 15 to 44 years [10], there is an
urgent need to build evidence about effective response
to this complex social problem in primary care. An
‘effective’ response not only requires an assessment of
the safety of women and children, it must also respect
Figure 2 weave causal model.
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Page 9 of 11and promote the dignity of women, validate and under-
stand the diversity of women’s experiences, withhold
j u d g e m e n ta b o u tw h a taw o m a ns h o u l dd oa n dw h e n ,
and place ongoing support at the centre of the interac-
tion between the woman and practitioner.
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